287 related articles for article (PubMed ID: 15477583)
1. Clinical trials of neuroprotection for Parkinson's disease.
LeWitt PA
Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
[No Abstract] [Full Text] [Related]
2. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Jenner P
Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
[No Abstract] [Full Text] [Related]
3. Selegiline's neuroprotective capacity revisited.
Riederer P; Lachenmayer L
J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
[No Abstract] [Full Text] [Related]
4. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Youdim MB; Riederer PF
Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
[No Abstract] [Full Text] [Related]
5. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
6. Reexamination of the TEMPO Study.
Shults CW
Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
[No Abstract] [Full Text] [Related]
7. Neuroprotection by selegiline and other MAO inhibitors.
Stern G
J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
[TBL] [Abstract][Full Text] [Related]
8. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
9. The comparative effects of medical therapies for Parkinson's disease.
Horn S; Stern MB
Neurology; 2004 Oct; 63(7 Suppl 2):S7-12. PubMed ID: 15477585
[No Abstract] [Full Text] [Related]
10. Monoamine oxidase inhibitors--is it time to up the TEMPO?
Rascol O
Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
[No Abstract] [Full Text] [Related]
11. [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Rákóczi K; Klivényi P; Vécsei L
Ideggyogy Sz; 2009 Jan; 62(1-2):25-34. PubMed ID: 19248724
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
13. [The early therapy challenge].
Reichmann H
Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310
[No Abstract] [Full Text] [Related]
14. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Olanow CW
J Neural Transm Suppl; 1996; 48():75-84. PubMed ID: 8988463
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Jost WH; Friede M; Schnitker J
Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
[No Abstract] [Full Text] [Related]
16. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
17. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
Schneider E
J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
[TBL] [Abstract][Full Text] [Related]
18. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
19. Future therapies for Parkinson's disease.
Hauser RA; Lyons KE
Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
[No Abstract] [Full Text] [Related]
20. Preclinical versus clinical neuroprotection.
Grünblatt E; Schlösser R; Gerlach M; Riederer P
Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
[No Abstract] [Full Text] [Related]
[Next] [New Search]